Japan· JP-2329009F1110

スルピリド

A sulpiride product containing スルピリド, registered in Japan by 日医工, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

On Japan’s NHI price listATC N05AL01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedスルピリドATCN05AL01REGISTER NO.JP-2329009F1110PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Sulpiride is registered in 12 of 19 countries.

Countries holding a registration under ATC N05AL01 (sulpiride), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 7 of them publish a price we can compare per daily dose

Sulpiride · ATC N05AL01

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sulpiride costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), the median price runs from $1.00 in France to $3.83 in Switzerland — a ×3.8 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Sulpiride · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.83
  • FR France$1.00
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
スルピリド
Manufacturer
日医工
Country
Japan (JP)
ATC code
N05AL01
ATC class
Sulpiride
Defined daily dose
0.8 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

23 interactions on record for sulpiride.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sulpiride · interactions on record

23 records

23 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b1ad84f3-2f3e-4fb2-a5cc-a1f94563d64d
GET /v1/drugs/b1ad84f3-2f3e-4fb2-a5cc-a1f94563d64d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "50mg1錠",
  "marks": "局",
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2329009F1110",
  "category": "内用薬",
  "price_yen": 10.8,
  "generic_name": "スルピリド",
  "product_name_jp": null,
  "therapeutic_class": "2329",
  "transitional_expiry": null
}

See everything about sulpiride.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.